论文部分内容阅读
目的检测c-Met蛋白在甲状腺癌及癌旁甲状腺组织中的表达,并分析c-Met蛋白表达与甲状腺乳头状癌患者临床病理特征的关系。方法采用免疫组织化学En Vision二步法检测81例甲状腺癌组织及52例癌旁甲状腺组织中c-Met蛋白的表达。结果甲状腺癌和癌旁甲状腺组织中c-Met蛋白阳性率分别为46.9%(38/81)和7.7%(4/52),两者比较有统计学差异(P<0.01)。其中甲状腺乳头状癌中c-Met蛋白阳性率50.8%(31/61),髓样癌中阳性率60.0%(3/5),均高于滤泡癌26.7%(4/15),但均无统计学差异(均P>0.05)。甲状腺乳头状癌c-Met蛋白表达与患者各项临床病理特征均无相关性(均P>0.05)。结论甲状腺癌中c-Met表达增强,其高表达可能与甲状腺癌发生相关,有望成为抗甲状腺癌治疗的一个潜在靶点。
Objective To detect the expression of c-Met protein in thyroid cancer and paracancer thyroid tissue, and to analyze the relationship between the expression of c-Met protein and clinicopathological features in patients with papillary thyroid carcinoma. Methods Immunohistochemistry En Vision two-step method was used to detect the expression of c-Met protein in 81 cases of thyroid carcinoma and 52 cases of paracancerous thyroid tissue. Results The positive rates of c-Met protein in thyroid cancer and adjacent normal thyroid tissues were 46.9% (38/81) and 7.7% (4/52), respectively. There was a significant difference between the two groups (P <0.01). The positive rate of c-Met protein in thyroid papillary carcinoma was 50.8% (31/61) and that in medullary carcinoma was 60.0% (3/5), both of which were higher than that of follicular carcinoma (26.7%, 4/15) No statistical difference (all P> 0.05). The expression of c-Met protein in papillary thyroid carcinoma had no correlation with clinicopathological features (all P> 0.05). Conclusions The expression of c-Met in thyroid cancer is increased. The high expression of c-Met may be related to the occurrence of thyroid cancer, which may be a potential target for anti-thyroid cancer therapy.